Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux

(2016) Varman T. Samuel et al.   JOURNAL OF CLINICAL INVESTIGATION

Supramolecular biomaterials

(2016) Matthew J. Webber et al.   NATURE MATERIALS

Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management

(2016) Khurum H. Khan et al.   ONCOLOGIST

P-selectin is a nanotherapeutic delivery target in the tumor microenvironment

(2016) Y. Shamay et al.   Science Translational Medicine

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

(2016) Cristian Massacesi et al.   OncoTargets and Therapy

MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma

(2015) S. Mohan et al.   CLINICAL CANCER RESEARCH

Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384

(2015) A. J. Leiker et al.   CLINICAL CANCER RESEARCH

Taselisib (GDC-0032), a Potent  -Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations

(2015) Z. S. Zumsteg et al.   CLINICAL CANCER RESEARCH

Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma

(2015) Dominik Horn et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

(2015) Donavan T. Cheng et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation

(2015) Mahmoud Toulany et al.   SEMINARS IN CANCER BIOLOGY

Targeting P-Selectin by Gallium-68–Labeled Fucoidan Positron Emission Tomography for Noninvasive Characterization of Vulnerable Plaques

(2014) Xiang Li et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas

(2014) Tanguy Y. Seiwert et al.   CLINICAL CANCER RESEARCH

Characterization of the Novel and Specific PI3K  Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

(2014) C. Fritsch et al.   MOLECULAR CANCER THERAPEUTICS

Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: A systematic review and meta-analysis of published studies

(2014) Fausto Petrelli et al.   ORAL ONCOLOGY

Reversible changes in pancreatic islet structure and function produced by elevated blood glucose

(2014) Melissa F. Brereton et al.   Nature Communications

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

(2013) Pascal Furet et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

(2013) A. Herzog et al.   CLINICAL CANCER RESEARCH

Development of PI3K inhibitors: lessons learned from early clinical trials

(2013) Jordi Rodon et al.   Nature Reviews Clinical Oncology

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110  Inhibitors in PIK3CA-Mutant Breast Cancer

(2013) M. Elkabets et al.   Science Translational Medicine

Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers

(2013) V. W. Y. Lui et al.   Cancer Discovery

Copy Number Amplification of the PIK3CA Gene Is Associated with Poor Prognosis in Non-lymph node metastatic Head and Neck Squamous Cell Carcinoma

(2012) Toshihito Suda et al.   BMC CANCER

Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

(2012) C. Garcia-Garcia et al.   CLINICAL CANCER RESEARCH

Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

(2012) Naifa L. Busaidy et al.   JOURNAL OF CLINICAL ONCOLOGY

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

Radiolabeled Fucoidan as a P-Selectin Targeting Agent for In Vivo Imaging of Platelet-Rich Thrombus and Endothelial Activation

(2011) F. Rouzet et al.   JOURNAL OF NUCLEAR MEDICINE

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

(2011) V Serra et al.   ONCOGENE

Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia

(2008) M.-C. Crouthamel et al.   CLINICAL CANCER RESEARCH